Study of clonal hematopoiesis of undetermined potential (CHIP) and proinflammatory biomarkers in patients with early in-stent occlusion after recanalizatio

Recruiting

Conditions: I70.2
Atherosclerosis of arteries of extremities

Registration Number: DRKS00034395

Lead Sponsor: niversitätsklinikum Augsburg

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 25

Inclusion Criteria

Competent patients who have been informed about the study both in writing and orally and have agreed to participate.
Women and men with PAOD stages IIb-IV who are undergoing either a first intervention with stent placement or a reintervention for stent occlusion.
Evidence of high-grade peripheral arterial stenoses demonstrated by duplex ultrasound (FKDS), CT, or MRI.

Exclusion Criteria

Patients with a tumor diagnosis
Patients with a known coagulation disorder
Patients under guardianship
Patients with a contraindication to the recommended antiplatelet therapy
Patients who have prematurely discontinued or paused the recommended antiplatelet therapy

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Frequency of CHIP Mutations in aarly stent occlusion ( <1year):<br>Determine if CHIP mutations (e.g., TET2 gene) are more frequent in patients experiencing early re-occlusion (within 1 year) after peripheral recanalization with stent implantation compared to a control group with long-term successful outcomes.<br><br>2. Correlation between CHIP mutations and early stent occlusions:<br>Evaluate the correlation between the presence of CHIP mutations and early re-occlusions (within 1 year) after stent implantation in patients with peripheral arterial occlusive disease (PAOD)

Secondary Outcome Measures

Name	Time	Method
1. Increased/decreased levels of certain cytokines<br> Assess if there is a biological correlate in terms of increased or decreased concentrations of specific cytokines associated with early re-occlusions (within 1 year) after peripheral recanalization with stent implantation.<br><br>2. Cytokine Concentrations in CHIP carriers vs. Non-CHIP carriers:<br>Compare the plasma concentrations of cytokines between CHIP carriers and non-CHIP carriers, both with and without stent occlusion.